

UGANDA Support for HPV Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uganda					
2. Grant number: 1720-UGA-19b-X / 18-UGA-19b-A					
3. Date of Decision Letter: 12 January 2018					
4. Date of the Partnership Framework Agreement: 28 June 2013					
5. Programme title: New Vaccine Support (NVS), HPV Routine					
6. Vaccine type: HPV					
7. Requested product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID					
8. Programme duration¹: 2015 -2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2015-2017	2018	2019	2020	Total ²
Programme Budget (US\$)	US\$16,803,821 ³	US\$1,838,500	US\$4,898,500	US\$5,091,500	US\$28,632,321
10. Vaccine introduction grant (in US\$): Not applicable					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁵					
Type of supplies to be purchased with Gavi funds in each year		2015-2017	2018		
Number of HPV vaccines doses			404,700		
Annual Amounts (US\$)		US\$16,803,821 ⁶	US\$1,838,500		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁵ This is the amount that Gavi has approved.

⁶ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Reference code: 1720-UGA-19b-X-C			
According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	18,700	49,700	51,700
Value of vaccine doses (US\$)	US\$83,849		
Total co-financing payments (US\$) (including freight)	US\$85,000	US\$226,000	US\$234,500
15. Operational support for campaigns: Not applicable			
16. Additional reporting requirements:			
Reports and other information		Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.		May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Secretariat	
17. Financial clarifications: Not applicable			
18. Other conditions: Not applicable			

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
12 January 2018